No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PBYI240517P5000
- 0.60
- +0.05+9.09%
15min DelayClose May 10 15:55 ET
0.60High0.60Low
0.60Open0.55Pre Close5 Volume282 Open Interest5.00Strike Price300.00Turnover200.71%IV-8.00%PremiumMay 17, 2024Expiry Date0.19Intrinsic Value100Multiplier5DDays to Expiry0.41Time Value100Contract SizeAmericanOptions Type-0.5135Delta0.3399Gamma8.37Leverage Ratio-0.0452Theta-0.0004Rho-4.30Eff Leverage0.0023Vega
Intraday
- 5D
- 1D
News
Puma Posts Lower Earnings After Sales Suffer Currency Headwind
By Pierre Bertrand Puma reported a decline in first-quarter earnings after sales were hit by unfavorable currency effects. The German sporting-goods company said it made 87.3 million euros ($93.9 mi
Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
Puma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Puma Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 43.44% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/01/2024 43.44% HC Wainwright & Co. $8 →
Earnings Call Summary | Puma Biotechnology(PBYI.US) Q1 2024 Earnings Conference
The following is a summary of the Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript:Financial Performance:Puma Biotechnology reported a total revenue of $43.8 million for Q1 2024, which
Comments
Puma biotech buys licenses for oncology treatments that have gone through testing, and brings them to market. I will hold until the ticker hits my target range (7-8 USD,) reevaluate (using FA and TA, and current market conditions to determine price channel and optimize execution,) and trade out.
1
$Puma Biotechnology(PBYI.US$ 🐂 like about to run 👍🏻but i am out this one frustrated me in past days
loading...
1
3
$Puma Biotechnology(PBYI.US$ • Puma Biotechnology (NASDAQ:PBYI) announced Wednesday that the U.S. FDA has greenlighted a Phase 2 trial to investigate its oral kinase inhibitor alisertib, in-licensed from Takeda (NYSE:TAK), in patients with breast cancer.
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• ...
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• ...
1
Puma Biotechnology's high P/E ratio is alarming due to its falling earnings. Despite investor hopes for a business turnaround, analysts remain skeptical. The high P/E and anticipated future earnings drop make current prices seem unjustifiable unless conditions drastically improve.
2
Read more